This Article Full Text (PDF) All Versions of this Article: 0897190008322247v1 22/1/53    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hegge, K. A. Articles by Haack, S. L. Search for Related Content Social Bookmarking                         What's this?

New Therapies for Osteoporosis

Penn Avenue Internal Medicine, Drake University College of Pharmacy and Health Sciences, Des Moines, Iowa, South Dakota State University College of Pharmacy, 2205 Career Avenue, Sioux Falls, SD 57106, karly.hegge{at}sdstate.edu

Anisa S. Fornoff, PharmD

Community Support Advocates and Progress Industries, Drake University College of Pharmacy and Health Sciences, Des Moines, Iowa

Sheryl L. Gutierres, PharmD

La Clinica de la Esperanza, Drake University College of Pharmacy and Health Sciences, Des Moines, Iowa

Sally L. Haack, PharmD

Community Access Pharmacy, Drake University College of Pharmacy and Health Sciences, Des Moines, Iowa

Osteoporosis is a growing health concern in the United States, with an enormous impact on morbidity and mortality. Despite published guidelines to aid clinicians in its management, several controversies remain. Many trials evaluate surrogate measures of bone strength rather than more clinically relevant outcomes, including fracture. Furthermore, the role of combination and sequential therapy remains unclear. Limited data are available regarding appropriate duration of therapy, management of osteoporosis in men, and treatment of glucocorticoid-induced osteoporosis. The development of unique therapeutic agents could potentially revolutionize the treatment of osteoporosis. Once yearly zoledronic acid may provide advantages over existing therapies. Because of limitations with existing selective estrogen receptor modulators, the search for agents with better efficacy and safety profiles has led to the development of several new medications within this class. Finally, denosumab, a monoclonal antibody to receptor activator for nuclear factor-kappa B ligand, also represents a novel therapeutic option for osteoporosis.

Key Words: osteoporosis • bisphosphonates • zoledronic acid • selective estrogen receptor modulators • denosumab

This version was published on February 1, 2009

Journal of Pharmacy Practice, Vol. 22, No. 1, 53-64 (2009)
DOI: 10.1177/0897190008322247


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?